News

Risankizumab is the latest biologic approved by the FDA and the first-ever IL-23A targeted therapy approved for the treatment of patients with Crohn's disease.

The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.

In new research, an association between food allergies and atopic dermatitis was highlighted, suggesting the need for further research.

The FDA has set a PDUFA date for daprodustat for February 1 for adult patients with chronic kidney disease.

"All forms of arthritis can make life difficult for people because of the pain, swelling, or stiffness in a joint or joints, and because of difficulties in getting about," investigators explained.

Dr. Ian Flinn says many patients opt for treatment with Bruton's tyrosine kinase (BTK) over combination therapy.

New data from the AHA 2023 Statistical Update suggest more people died from cardiovascular-related causes in 2020 than in any year since 2003.

“Our primary motivation was to help develop treatments for people with osteoarthritis that would slow or prevent the disease and be more than painkillers- actually affect the disease process itself,” Virginia Kraus, MD, explains.

The specific mechanisms involved in associations between air pollution and respiratory illness without viral infection are not understood, especially compared with those of respiratory viruses and asthma exacerbation.

The risk of diabetes was reduced by approximately 50% in both the vigorous and moderate aerobic exercise groups compared with the nonexercise group.

Crosbie presented results from a small pilot study testing a video game platform for patients with executive function deficits during the annual APSARD meeting.

A systematic review and meta-analysis of nearly 3 dozen published articles details the apparent increase in risk of cardiovascular disease and diabetes associated with a diagnosis of autism.

New research, comparable with that of the NAVIGATE trial, was conducted and showed strong results for the use of guselkumab for psoriasis patients.

The 2 strains identified were highly similar and exhibited differences of only 2 single-nucleotide polymorphisms.

In this episode of Diabetes Dialogue, ours hosts discuss the clearance of Tidepool Loop, what is unique about the app’s customizability and compatibility with other diabetes technologies, and other top points for people with diabetes and members of the diabetes care team to consider with the technology moving into the future.

In a recent study, DLE patients responded well to topical niacinamide 2% and 4% as adjuvant therapy, with strong results and few side effects.

The January 2023 rheumatology month in review highlights a recent study that indicated an increased risk of hospitalization and death among patients with gout and COVID-19, the expansion of research evaluating adalimumab biosimilars, and trends in fibromyalgia.

An FDA panel voted unanimously this week to support harmonizing an annual primary and booster dose, moving public health strategies to reflect the endemic course of COVID-19.

A lower DME resolution rate was associated with a thicker baseline CST and better baseline best-corrected visual acuity in eyes treated with aflibercept.

A new review shows a majority of COVID-19 randomized, controlled trial preprints have been published with changes to the components of the original findings.

SARS-CoV-2 infections cause microbiome dysbiosis in patient and possibly an increase in opportunistic pathogens and a decrease in beneficial bacteria.

The January 2023 cardiology month in review features a trio of articles related to management of atrial fibrillation, the FDA approval of Abbott’s Navitor system, and a study spotlighting the prevalence of mental health conditions among cardiologists.

In this recent study, mental health conditions associated with alopecia areata were assessed by the study’s investigators.

A sugary drinks tax in England may have prevented over 5,000 cases of obesity a year in older girls, but had no significant association with obesity levels in year six boys or younger children.

The approval of the adalimumab biosimilar, adalimumab-aacf, signals the beginning of Fresenius Kabi's long-term dedication to biosimilars.

The clinical trials that supported the FDA decision, SEQUOIA and ALPINE, evaluated the efficacy of zanubrutinib and findings paved the way to add the therapy as a treatment option.

A ED screening program identified a substantial number of patients with undiagnosed prediabetes and T2D or undermanaged disease, particularly racial and ethnic minorities.

The latest HCPLive interview segment with Karan Lal, DO, discussing his views on what can go wrong during cosmetic procedures.

The study population consists of patients who received 1-3 prior lines of therapy for relapsed and lenalidomide-refractory multiple myeloma.

Glucocorticoids are sometimes used as “bridging” therapy to alleviate symptoms in newly diagnosed patients with rheumatoid arthritis until a disease-modifying antirheumatic drug (DMARD) kicks in. Test your knowledge of bridging therapy with this quiz.